||A major contributor to this article appears to have a close connection with its subject. (March 2015)|
|This article needs additional citations for verification. (January 2010)|
|Traded as||NYSE: ACT
S&P 500 Component
|Industry||Brand and generic pharmaceuticals, and pharmaceutical research and development.|
|Founded||Libertyville, Illinois, United States (Spring 1984)|
|Founder||Allen Chao, Ph.D. and David Hsia, Ph.D.|
|Headquarters||Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States.|
Number of locations
|40 manufacturing facilities, 27 global R&D centers and marketing/sales facilities worldwide.|
|Paul Bisaro, Executive Chairman, Brenton L. Saunders CEO & President|
|Products||Brand and generic pharmaceuticals|
|Revenue||US$ 13 billion(2014)|
Number of employees
|~30,000 employees worldwide (2015)|
Actavis plc (NYSE: ACT) is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis markets a portfolio of brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. The company's product portfolio includes Botox, Namenda, Restasis, Linzess, Bystolic, Juvederm, Latisse, Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex, Optive, Natrelle, Viibryd, Liletta, Saphris, Enablex, Actonel, Androderm, Gelnique and others.
Actavis also operates the world's third-largest generics business. The company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.
Actavis is also developing biosimilars products in oncology and other therapeutic categories, and currently has a portfolio of five biosimilar products in development.
Actavis has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.
The company was founded in the spring of 1983, when, with funding from friends and family, colleagues Allen Chao, Ph.D. and David Hsia, Ph.D., began a small drug development enterprise. Just two months later, the founders established an initial product development and analytical laboratory with six employees (including both founders) in a leased space in Libertyville, Illinois.
By late fall of the same year, the company moved to Southern California into an initial 2,000-square-foot (190 m2) leased facility in Corona, and the development and manufacturing of generic pharmaceuticals began. The Corona site became the corporate headquarters for the rapidly expanding U.S. company.
Throughout its history, Actavis has expanded both organically and as the result of strategic acquisitions that brought broader product lines, enhanced drug delivery technologies, and ultimately branded pharmaceutical products to the company. In 1993, Actavis, then Watson, announced its initial public offering (IPO) of shares of common stock. The company was initially listed on the NASDAQ under the ticker symbol WATS. The company moved to the New York Stock Exchange (NYSE) in 1997, and began trading under the symbol WPI.
2000 to 2009
In 2000, the company acquired Schein Pharmaceutical, Inc., an acquisition that more than doubled the company’s size. In that same year, the group reported revenues in excess of $1 billion. In the fall of 2006, it acquired Andrx Corporation, a Fort Lauderdale, FL–based pharmaceutical company, making it the third largest specialty pharmaceutical company based on total prescriptions dispensed. In 2007, Dr. Allen Chao retired as President and Chief Executive Officer (CEO) and was succeeded by Paul M. Bisaro. The company’s international presence began with the acquisition of the Arrow Group in 2009, providing the company with commercial presence in more than 20 international markets. As a result of the Arrow acquisition, the company also acquired the biopharmaceutical development organization Eden Biodesign in Liverpool, UK.
2011 to the present day
The company increased its presence in Europe with the acquisition of Specifar Pharmaceuticals S.A. in May 2011. Based in Athens, Greece, Specifar is a generic pharmaceutical developer, manufacturer and marketer of products sold under its own and customer labels. In December 2011, a collaboration agreement with Amgen was announced—to develop and commercialize oncology biosimilars.
In January 2012, the company acquired Ascent Pharmahealth Ltd, with an established commercial base in Malaysia, Hong Kong, Vietnam, and Thailand. In November 2012, Watson acquired the Switzerland based, global generics company Actavis Group for EUR4.25 billion, creating the world’s third largest generics company, with a leading position in key established commercial markets including the U.S., UK, Nordics, Canada, Australia, and emerging markets in Central and Eastern Europe, and Russia. Following the acquisition, Watson adopted Actavis' name for its global operations.
In 2011, the company moved its corporate headquarters from Corona, California to Parsippany, New Jersey. The new LEED-certified corporate headquarters at the Morris Corporate Center in Parsippany was formally dedicated on June 9, 2011.
On October 1, 2013 Actavis acquired Irish pharmaceutical company Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. The combination created a company with approximately $10 billion in anticipated combined annual 2013 revenue, and the third-largest U.S. specialty pharmaceutical company with approximately $3 billion in annual revenue focused on the core therapeutic categories of women’s health, urology, gastroenterology and dermatology. In association with the merger the company relocated its corporate headquarters to Ireland while maintaining its operational headquarters in Parsippany, taking advantage of the lower (17% vs. 35% in the United States) Irish corporate tax rate. This deal inspired a series of similar moves by other drug companies and led to new Treasury Department regulations limiting the ability of companies to perform such inversions, although Actavis was exempt from these regulations as its move abroad had already been completed. CEO Paul Bisaro stated that in making the inversion, they were trying to "level the playing field" given the high corporate tax rate in the United States.
On July 1, 2014 Actavis announced that it had completed its acquisition of Forest Laboratories in a cash and equity transaction valued at approximately $25 billion. Following the acquisition, the company restructured its executive leadership, with Paul Bisaro being named Executive Chairman, and Brent Saunders being appointed CEO and President of the combined organization.
In November 2014 Actavis acquired Durata Therapeutics giving the company access to the already-marketed infectious disease drug, dalbavancin. On October 22, 2014 the company announced an option to acquire Rhythm Health including its Phase IIb-ready drug candidate relamorelin (RM-131), a peptide ghrelin agonist, designed to treat diabetic gastroparesis.
In November 2014 Actavis announced its intention to acquire Allergan, the manufacturer of Botox Completion of the deal would increase its market capitalization to $147 billion. On March 17, 2015, Actavis completed the acquisition of Allergan in a cash and equity transaction valued at approximately $70.5 billion. The combination created a $23 billion diversified global pharmaceutical company with commercial reach across 100 countries.
Locations and facilities
The company has 40 manufacturing facilities in five continents providing the company with a core leadership position in modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables.
The company’s manufacturing facilities are located in Belgium, Brazil Bulgaria, Canada, China, France, Germany, Greece, Iceland, India, Indonesia, Ireland, Northern-Ireland, Italy, Malta, Puerto Rico, Romania, Singapore, Serbia, Thailand, UK and USA.
Research and development facilities
Actavis has 27 global R&D facilities focusing on the development of modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables around the world.
The company’s R&D facilities are located in Belgium, Bulgaria, China, France, Iceland, Italy, India, Indonesia, Ireland, Japan, Northern Ireland, Romania, UK and USA.
- "Actavis plc". MarketWatch.
- "Form 10K". Actavis plc.
- "Botox cosmetics". Allergan.
- "Restasis". Allergan.
- "Bystolic". Actavis.
- "Juvederm". Allergan.
- "Latisse". Allergan.
- "Ozurdex". Allergan.
- "Optive". Allergan.
- "Natrelle". Allergan.
- "Form 10K". Actavis plc.
- "Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES Patent Suit". First Word Pharma.
- John Carroll. "Can Actavis deliver a promised $6B boost from this pipeline". Fierce Biotech.
- "Actavis Confirms Favorable Ruling In Generic Pulmicort Respules Patent Suit". First Word Pharma.
- "Actavis Adopting Allergan Name; Earnings Soar as Closing of Deal Looms". WSJ. 2015-02-18. Retrieved 2015-02-19.
- "ACT Profile - Actavis plc Ordinary Shares Stock - Yahoo! Finance". yahoo.com.
- "Watson Pharmaceuticals acquired Arrow Group for 1.75B". TBI.
- "Watson Pharmaceuticals agrees to buy a rival". NY Times.
- "WATSON PHARMACEUTICALS TO BUY ANDRX CORP". PharmacyTimes.com.
- "Watson Pharmaceuticals, Inc. Says CEO to Retire, Names Replacement". Fierce Biotech.
- Shannon Pettypiece. "Watson Agrees to Buy Arrow Group for $1.75 Billion". Bloomberg.
- Gareth Macdonald. "Watson buys Eden Biodesign". Biopharma-Reporter.com.
- Lewis Krauskopf. "Watson Pharma buys Greece's Specifar for $562 million". Reuters.
- Ryan McBride. "Amgen and Watson strike $400M cancer biosimilars pact". Fierce Biotech.
- "Watson buys Ascent Pharmahealth". Finance Yahoo.
- Eyk Henning. "Watson, Actavis to Merge in €4.5 Billion Deal". Wall Street Journal.
- "Generic drug maker Watson opening research operations in North Brunswick". NJ.com.
- "News - Actavis". Actavis.
- "Actavis to Buy Warner Chilcott in $5 Billion Deal". The Wall Street Journal.
- "Allergan Escapes Valeant’s Pursuit, Agreeing to Be Bought by Actavis". The New York Times.
- Drew Armstrong. "Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal". Bloomberg.com.
- "Actavis to buy Forest Laboratories for 25 billion". Bloomberg.
- "GEN - News Highlights:Actavis Deal's a Dandy for Activist Icahn". GEN.
- "GEN - News Highlights:Actavis to Acquire Durata for $675M+". GEN.
- "GEN - News Highlights:Actavis Signs $40M+ Option to Buy Rhythm Health, Relamorelin". GEN.
- "GEN - News Highlights:Actavis-Adamas Alzheimer's Treatment Wins FDA Nod". GEN.
- "BBC News - Actavis to buy Botox-maker Allergan $66bn". BBC News.
- Caroline Chen. "Actavis Surges to Top Drugmaker Ranks With Acquisitions". Bloomberg.com.
- "The Morning Ledger: Actavis Could Again Evade Treasury’s Grasp for Post-Inversion Tax Break". WSJ.
- "Actavis plc". MarketWatch.